Skip to main content

Advertisement

Table 2 Adverse events associated with different neoadjuvant therapy in patients with renal cell carcinoma

From: Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

Adverse event Axitinib [cases (%)] Sunitinib [cases (%)] Sorafenib [cases (%)] P 1 P 2 P 3
All grade Grade 1–2 Grade 3–4 All grade Grade 1–2 Grade 3–4 All grade Grade 1–2 Grade 3–4
Hand–foot syndrome 6 (40.0) 5 (33.3) 1 (6.7) 13 (54.2) 10 (41.7) 3 (12.5) 16 (53.3) 13 (43.3) 3 (10.0) 0.389 0.399 0.951
Hypertension 6 (40.0) 5 (33.3) 1 (6.7) 11 (45.9) 8 (33.3) 3 (12.5) 13 (43.3) 10 (33.3) 2 (6.7) 0.721 0.831 0.854
Diarrhea 4 (29.4) 4 (29.4) 0 (0.0) 9 (37.5) 9 (37.5) 0 (0.0) 12 (40.0) 11 (36.7) 1 (3.3) 0.485 0.378 0.852
Nausea 4 (26.7) 4 (26.7) 0 (0.0) 8 (33.3) 8 (33.3) 0 (0.0) 8 (26.7) 8 (26.7) 0 (0.0) 0.092 1.000 0.594
Fatigue 4 (26.7) 4 (26.7) 0 (0.0) 7 (29.1) 7 (29.1) 0 (0.0) 8 (26.7) 8 (26.7) 0 (0.0) 0.150 1.000 0.839
Loss of appetite 3 (20.0) 3 (20.0) 0 (0.0) 6 (25.0) 6 (25.0) 0 (0.0) 7 (23.3) 7 (23.3) 0 (0.0) 0.718 0.800 0.887
Leukocytopenia 2 (13.3) 2 (13.3) 0 (0.0) 11 (45.9) 8 (33.3) 3 (12.5) 8 (26.7) 7 (23.3) 1 (3.3) 0.036 0.526 0.143
Thrombocytopenia 2 (13.3) 2 (13.3) 0 (0.0) 12 (50.0) 9 (37.5) 3 (12.5) 7 (23.3) 7 (23.3) 0 (0.0) 0.020 0.693 0.041
lymphocytopenia 2 (13.3) 3 (13.3) 0 (0.0) 8 (33.3) 5 (20.8) 3 (12.5) 4 (13.3) 4 (13.3) 0 (0.0) 0.310 1.000 0.079
Anemia 2 (13.3) 2 (13.3) 0 (0.0) 5 (20.8) 4 (15.8) 1 (4.2) 7 (23.3) 6 (20.0) 1 (3.3) 0.638 0.890 0.826
Hypothyroidism 2 (13.3) 2 (13.3) 0 (0.0) 6 (25.0) 8 (25.0) 0 (0.0) 4 (13.33) 4 (13.33) 0 (0.0) 0.638 1.000 0.457
  1. P1, axitinib vs. sunitinib; P2, axitinib vs. sorafenib; P3, sunitinib vs. sorafenib